Sign In
Section Navigation
Common TitleDRIVE AHEAD
Official Title A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Fixed-dose Combination Doravirine-Tenofovir disoproxil fumarate-Lamivudine (MK-1439A) Once-Daily Versus ATRIPLA™ Once-Daily in Treatment-Naïve HIV-1 Infected Subjects
Phase Phase III
ClinicalTrials.gov NCT02403674
Treatments
Doravirine
Doravirine Pifeltro

Doravirine

Tradename:PifeltroOther Names:DORClass:Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
,
Doravirine-Tenofovir DF-Lamivudine
Doravirine-Tenofovir DF-Lamivudine Delstrigo

Doravirine-Tenofovir DF-Lamivudine

Tradename:DelstrigoOther Names:DOR-TDF-3TC, Doravirine-Tenofovir disoproxil fumarate-LamivudineClass:Single-Tablet Regimens
Categories Treatment-Naive
Funding
IndustryMerck
References
  • Orkin C, Squires KE, Molina JM, et al. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. Clin Infect Dis. 2019;68:535-44.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.